Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

457 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
HMG-CoA reductase expression in breast cancer is associated with a less aggressive phenotype and influenced by anthropometric factors.
Borgquist S, Djerbi S, Pontén F, Anagnostaki L, Goldman M, Gaber A, Manjer J, Landberg G, Jirström K. Borgquist S, et al. Int J Cancer. 2008 Sep 1;123(5):1146-53. doi: 10.1002/ijc.23597. Int J Cancer. 2008. PMID: 18528862
The incidence of tumours with a high HMG-CoAR-expression was increased among HRT-users, although this was not statistically significant in a heterogeneity analysis. Obesity was significantly associated with a high HMG-CoAR expression assessed both as a
The incidence of tumours with a high HMG-CoAR-expression was increased among HRT-users, although this was not statistically significa …
A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer.
Eberhard J, Gaber A, Wangefjord S, Nodin B, Uhlén M, Ericson Lindquist K, Jirström K. Eberhard J, et al. Br J Cancer. 2012 Feb 28;106(5):931-8. doi: 10.1038/bjc.2012.34. Epub 2012 Feb 14. Br J Cancer. 2012. PMID: 22333599 Free PMC article.
BACKGROUND: Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of SATB2 has been linked to poor survival from the disease. In this study, we validated the prognostic ability of SATB2 expression in a l …
BACKGROUND: Special AT-rich sequence-binding protein 2 (SATB2) is a novel diagnostic marker of colorectal cancer (CRC), and loss of S …
High expression of tumour-associated trypsin inhibitor correlates with liver metastasis and poor prognosis in colorectal cancer.
Gaber A, Johansson M, Stenman UH, Hotakainen K, Pontén F, Glimelius B, Bjartell A, Jirström K, Birgisson H. Gaber A, et al. Br J Cancer. 2009 May 19;100(10):1540-8. doi: 10.1038/sj.bjc.6605047. Epub 2009 Apr 21. Br J Cancer. 2009. PMID: 19384300 Free PMC article.
Moreover, a proinvasive function of TATI has been shown in colon cancer cell lines. In this study, we have examined the prognostic significance of tumour-specific TATI expression in colorectal cancer, assessed by immunohistochemistry (IHC) on tissue microarrays (TMAs) with …
Moreover, a proinvasive function of TATI has been shown in colon cancer cell lines. In this study, we have examined the prognostic si …
Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer.
Larsson A, Johansson ME, Wangefjord S, Gaber A, Nodin B, Kucharzewska P, Welinder C, Belting M, Eberhard J, Johnsson A, Uhlén M, Jirström K. Larsson A, et al. Br J Cancer. 2011 Aug 23;105(5):666-72. doi: 10.1038/bjc.2011.295. Epub 2011 Aug 9. Br J Cancer. 2011. PMID: 21829192 Free PMC article.
METHODS: Using tissue microarrays and immunohistochemistry, PODXL expression was evaluated in 536 incident CRC cases from a prospective, population-based cohort study. ...Our results also suggest that PODXL may be a useful marker to stratify patients for adjuvant ch …
METHODS: Using tissue microarrays and immunohistochemistry, PODXL expression was evaluated in 536 incident CRC cases from a prospecti …
High nuclear RBM3 expression is associated with an improved prognosis in colorectal cancer.
Hjelm B, Brennan DJ, Zendehrokh N, Eberhard J, Nodin B, Gaber A, Pontén F, Johannesson H, Smaragdi K, Frantz C, Hober S, Johnson LB, Påhlman S, Jirström K, Uhlen M. Hjelm B, et al. Proteomics Clin Appl. 2011 Dec;5(11-12):624-35. doi: 10.1002/prca.201100020. Proteomics Clin Appl. 2011. PMID: 21956899
A peptide suspension bead array assay confirmed the five epitopes of the polyclonal antibody, while only one of the monoclonal antibodies could be mapped using this approach. ...
A peptide suspension bead array assay confirmed the five epitopes of the polyclonal antibody, while only one of the monoclonal antibo
Validation of podocalyxin-like protein as a biomarker of poor prognosis in colorectal cancer.
Larsson A, Fridberg M, Gaber A, Nodin B, Levéen P, Jönsson G, Uhlén M, Birgisson H, Jirström K. Larsson A, et al. BMC Cancer. 2012 Jul 8;12:282. doi: 10.1186/1471-2407-12-282. BMC Cancer. 2012. PMID: 22769594 Free PMC article.
METHOD: PODXL protein expression was analyzed by immunohistochemistry in tissue microarrays with tumour samples from a consecutive, retrospective cohort of 270 CRC patients (cohort 1) and a prospective cohort of 337 CRC patients (cohort 2). ...The results further un …
METHOD: PODXL protein expression was analyzed by immunohistochemistry in tissue microarrays with tumour samples from a consecutive, r …
Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer.
Michaut M, Chin SF, Majewski I, Severson TM, Bismeijer T, de Koning L, Peeters JK, Schouten PC, Rueda OM, Bosma AJ, Tarrant F, Fan Y, He B, Xue Z, Mittempergher L, Kluin RJ, Heijmans J, Snel M, Pereira B, Schlicker A, Provenzano E, Ali HR, Gaber A, O'Hurley G, Lehn S, Muris JJ, Wesseling J, Kay E, Sammut SJ, Bardwell HA, Barbet AS, Bard F, Lecerf C, O'Connor DP, Vis DJ, Benes CH, McDermott U, Garnett MJ, Simon IM, Jirström K, Dubois T, Linn SC, Gallagher WM, Wessels LF, Caldas C, Bernards R. Michaut M, et al. Sci Rep. 2016 Jan 5;6:18517. doi: 10.1038/srep18517. Sci Rep. 2016. PMID: 26729235 Free PMC article.
We have performed a comprehensive genomic, transcriptomic and proteomic analysis of a large ILC patient cohort and present here an integrated molecular portrait of ILC. ...Using the somatic mutation rate and eIF4B protein level, we identified three groups with diffe …
We have performed a comprehensive genomic, transcriptomic and proteomic analysis of a large ILC patient cohort and present her …
Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer.
Li B, Ni Chonghaile T, Fan Y, Madden SF, Klinger R, O'Connor AE, Walsh L, O'Hurley G, Mallya Udupi G, Joseph J, Tarrant F, Conroy E, Gaber A, Chin SF, Bardwell HA, Provenzano E, Crown J, Dubois T, Linn S, Jirstrom K, Caldas C, O'Connor DP, Gallagher WM. Li B, et al. Cancer Res. 2017 Jul 15;77(14):3834-3845. doi: 10.1158/0008-5472.CAN-16-2546. Epub 2017 Apr 28. Cancer Res. 2017. PMID: 28455421
Here, we report evidence highlighting the cell-cycle-related kinase CDK7 as a driver and candidate therapeutic target in TNBC. ...Collectively, our results highlight elevated CDK7 expression as a candidate biomarker of poor prognosis in TNBC, and they offer a
Here, we report evidence highlighting the cell-cycle-related kinase CDK7 as a driver and candidate therapeutic target in TNBC. ...Col …
S100A9 expressed in ER(-)PgR(-) breast cancers induces inflammatory cytokines and is associated with an impaired overall survival.
Bergenfelz C, Gaber A, Allaoui R, Mehmeti M, Jirström K, Leanderson T, Leandersson K. Bergenfelz C, et al. Br J Cancer. 2015 Oct 20;113(8):1234-43. doi: 10.1038/bjc.2015.346. Epub 2015 Oct 8. Br J Cancer. 2015. PMID: 26448179 Free PMC article.
S100A9 is a calcium-binding protein that is associated with inflammation and expressed not only in myeloid cells but also in some tumours. ...CONCLUSION: We suggest that S100A9 could be viewed as a novel therapeutic target for patients with ER(-)PgR(-) breast cancer …
S100A9 is a calcium-binding protein that is associated with inflammation and expressed not only in myeloid cells but also in some tum …
Low RBM3 protein expression correlates with clinical stage, prognostic classification and increased risk of treatment failure in testicular non-seminomatous germ cell cancer.
Olofsson SE, Nodin B, Gaber A, Eberhard J, Uhlén M, Jirström K, Jerkeman M. Olofsson SE, et al. PLoS One. 2015 Mar 26;10(3):e0121300. doi: 10.1371/journal.pone.0121300. eCollection 2015. PLoS One. 2015. PMID: 25811459 Free PMC article.
RESULTS: In the entire cohort, there was a significant association between clinical stage (p=0.044) and RBM3 expression. Weak RBM3 expression correlated with a significantly reduced FFS [79.3% versus 90.4% (p=0.019)] and CSS [87.5% versus 97.3% (p=0.047)]. ...These …
RESULTS: In the entire cohort, there was a significant association between clinical stage (p=0.044) and RBM3 expression. Weak RBM3 ex …
457 results
Jump to page
Feedback